Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12695797 | 1.00 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13505492 | 1.00 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18045272 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL13505421 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL13505210 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12640788 | 0.90 | HTR3A (0.66) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12640582 | 0.90 | SLC18A3 (0.47) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5839498 | 0.90 | HTR3A (0.66) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4200479 | 0.88 | HTR3A (0.63) | HTR3A | |
| Hydrochloric Acid SCHEMBL12505060 | 0.88 | HTR3A (0.63) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | claimed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | claimed |
| CN-109134351-B | Synthesis method of S-3- (4-aminophenyl) piperidine | 武汉理工大学 | 2022-03-11 | — | — | CN | claimed |
| CN-107759506-B | Preparation method of nilapabu intermediate S-3- (4-bromophenyl) piperidine | 四川同晟生物医药有限公司 | 2021-04-23 | — | — | CN | claimed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | claimed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | claimed |
| CN-109134351-A | S-3-(4- aminophenyl) piperidines synthetic method | 武汉理工大学 | 2019-01-04 | — | — | CN | claimed |
| CN-107759506-A | A kind of Buddhist nun draws the preparation method of (4 bromophenyl) piperidines of Pabuk intermediate S 3 | 四川同晟生物医药有限公司 | 2018-03-06 | — | — | CN | claimed |
| EP-2895477-B1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2017-11-01 | — | — | EP | claimed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | claimed |
| CN-106749180-A | A kind of method for preparing PARP inhibitor Niraparib | 南京艾德凯腾生物医药有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106749181-A | A kind of method for preparing Ni Lapani | 南京艾德凯腾生物医药有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| US-9487501-B2 | Pyrazole carboxamide compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | claimed |
| EP-2895477-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | claimed |
| WO-2014041007-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | claimed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | claimed |
| CN-122059869-A | Method for synthesizing Nilapachone key intermediate | 南京正大天晴制药有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-120682137-A | Preparation method of nilaparib intermediate (S) -3- (4-aminophenyl) piperidine-1-tert-butyl formate | 南通常佑药业科技有限公司 | 2025-09-23 | — | — | CN | disclosed |
| CN-120682137-A | Preparation method of nilaparib intermediate (S) -3- (4-aminophenyl) piperidine-1-tert-butyl formate | 南通常佑药业科技有限公司 | 2025-09-23 | — | — | CN | disclosed |
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| CN-117964546-B | Preparation method of nilaparib intermediate | 成都硕德药业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117964546-A | Preparation method of nilaparib intermediate | 成都硕德药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024044657-A1 | BIOCATALYSTS AND METHODS THEREOF | TESARO, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-117538434-A | Detection method of nilaparib intermediate | 苏州正济医药研究有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-113637002-B | Preparation method of Nilaparib | 天津太平洋化学制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3694836-B1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB SHANGHAI CO LTD (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-3694836-B1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB SHANGHAI CO LTD (CN) | 2022-06-15 | — | — | EP | disclosed |
| CN-109134351-B | Synthesis method of S-3- (4-aminophenyl) piperidine | 武汉理工大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-109134351-B | Synthesis method of S-3- (4-aminophenyl) piperidine | 武汉理工大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-109134351-B | Synthesis method of S-3- (4-aminophenyl) piperidine | 武汉理工大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-113637002-A | Preparation method of Nilaparib | 天津太平洋化学制药有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-107759506-B | Preparation method of nilapabu intermediate S-3- (4-bromophenyl) piperidine | 四川同晟生物医药有限公司 | 2021-04-23 | — | — | CN | disclosed |
| CN-107759506-B | Preparation method of nilapabu intermediate S-3- (4-bromophenyl) piperidine | 四川同晟生物医药有限公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-10927077-B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2021-02-23 | — | — | US | disclosed |
| US-10927077-B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2021-02-23 | — | — | US | disclosed |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 2021-02-23 | — | — | US | disclosed |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 2021-02-23 | — | — | US | disclosed |
| US-20200385350-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20200385350-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-3668857-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2020-06-18 | — | — | US | disclosed |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2020-06-18 | — | — | US | disclosed |
| CN-109456253-B | Method for synthesizing (S) -3- (4-bromophenyl) -piperidine or salt thereof through chiral induction | 上海博璞诺科技发展有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3536690-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD Italia S.r.l. (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| WO-2019072237-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2019-04-18 | — | — | WO | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | disclosed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | disclosed |
| WO-2019036441-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS USA, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036441-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS USA, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| CN-109265390-A | A kind of preparation method and intermediate of the intermediate for synthesizing antineoplastic medicament niraparib | 再鼎医药(上海)有限公司 | 2019-01-25 | — | — | CN | disclosed |
| CN-109134351-A | S-3-(4- aminophenyl) piperidines synthetic method | 武汉理工大学 | 2019-01-04 | — | — | CN | disclosed |
| CN-109134351-A | S-3-(4- aminophenyl) piperidines synthetic method | 武汉理工大学 | 2019-01-04 | — | — | CN | disclosed |
| CN-109134351-A | S-3-(4- aminophenyl) piperidines synthetic method | 武汉理工大学 | 2019-01-04 | — | — | CN | disclosed |
| CN-108997313-A | PARP inhibitor key intermediate and preparation method thereof | 常州制药厂有限公司 | 2018-12-14 | — | — | CN | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| CN-107759506-A | A kind of Buddhist nun draws the preparation method of (4 bromophenyl) piperidines of Pabuk intermediate S 3 | 四川同晟生物医药有限公司 | 2018-03-06 | — | — | CN | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-2895477-B1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| CN-106986832-A | Vegfr3 inhibitor | 癌症治疗合作研究中心有限公司 | 2017-07-28 | — | — | CN | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| CN-106854176-A | A kind of method for preparing Ni Lapani tosilate monohydrates | 南京艾德凯腾生物医药有限责任公司 | 2017-06-16 | — | — | CN | disclosed |
| CN-106749180-A | A kind of method for preparing PARP inhibitor Niraparib | 南京艾德凯腾生物医药有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106749181-A | A kind of method for preparing Ni Lapani | 南京艾德凯腾生物医药有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| CN-106432054-A | Method for preparing 4-(piperidine-3-yl)aniline | 青岛云天生物技术有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432054-A | Method for preparing 4-(piperidine-3-yl)aniline | 青岛云天生物技术有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432055-A | Preparation method of niraparib intermediate 4-(piperidyl-3-yl)aniline | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432055-A | Preparation method of niraparib intermediate 4-(piperidyl-3-yl)aniline | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9487501-B2 | Pyrazole carboxamide compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-11-08 | — | — | US | disclosed |
| CN-106008460-A | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide | 默沙东有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | disclosed |
| EP-2895477-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| EP-2805945-A1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD Italia S.r.l. (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| WO-2014041007-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014027199-A1 | FAK AND FLT3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
| CN-103596951-A | 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer | AFRAXIS INC | 2014-02-19 | — | — | CN | disclosed |
| EP-2675793-A1 | FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| CN-101578279-B | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO | 2013-07-17 | — | — | CN | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012168260-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012110773-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | HTR3A 2293/4885CYP2D6 4188/4885SLC6A2 4326/4885 |
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | HTR3A 2064/4885CYP2D6 4301/4885SLC6A2 4828/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | HTR3A 933/4885CYP2D6 2324/4885SLC6A2 3741/4885 |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | PARP1, PARP2, PARP3 | HTR3A 3609/4885CYP2D6 712/4885SLC6A2 2935/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR3A 2847/4885CYP2D6 3687/4885SLC6A2 2761/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR3A 1320/4885CYP2D6 2362/4885SLC6A2 3597/4885 |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | HTR3A 79/4885CYP2D6 2615/4885SLC6A2 68/4885 |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HTR3A 248/4885CYP2D6 593/4885SLC6A2 59/4885 |
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | HTR3A 1037/4885CYP2D6 2507/4885SLC6A2 4523/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | HTR3A 74/4885CYP2D6 2946/4885SLC6A2 100/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR3A 2847/4885CYP2D6 3687/4885SLC6A2 2761/4885 |
| US-10927077-B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | PARP1, PARP2, TOP2B | HTR3A 4265/4885CYP2D6 1405/4885SLC6A2 4427/4885 |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | HTR3A 2217/4885CYP2D6 2747/4885SLC6A2 3683/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HTR3A 248/4885CYP2D6 593/4885SLC6A2 59/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | HTR3A 2847/4885CYP2D6 3687/4885SLC6A2 2761/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | HTR3A 3550/4885CYP2D6 4479/4885SLC6A2 1855/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | HTR3A 2064/4885CYP2D6 4301/4885SLC6A2 4828/4885 |
| US-20200385350-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | PARP1, PARP2, TOP2B | HTR3A 4265/4885CYP2D6 1405/4885SLC6A2 4427/4885 |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | PARP1, PARP2, PARP3 | HTR3A 3609/4885CYP2D6 712/4885SLC6A2 2935/4885 |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, SHBG | HTR3A 417/4885CYP2D6 4807/4885SLC6A2 3733/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HTR3A 248/4885CYP2D6 593/4885SLC6A2 59/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | HTR3A 1273/4885CYP2D6 2426/4885SLC6A2 4545/4885 |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HCRTR1, TAAR1, HCRTR2 | HTR3A 55/4885CYP2D6 555/4885SLC6A2 203/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR3A 2474/4885CYP2D6 3642/4885SLC6A2 2644/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | HTR3A 248/4885CYP2D6 593/4885SLC6A2 59/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | HTR3A 1037/4885CYP2D6 2507/4885SLC6A2 4523/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR3A 2474/4885CYP2D6 3642/4885SLC6A2 2644/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | HTR3A 1555/4885CYP2D6 4401/4885SLC6A2 4758/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | HTR3A 1032/4885CYP2D6 3804/4885SLC6A2 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.